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Hepatic triglyceride content does 
not affect circulating CETP: lessons 
from a liraglutide intervention trial 
and a population-based cohort
Huub J. van Eyk  1,2, Lisanne L. Blauw1,3, Maurice B. Bizino1,4, Yanan Wang1,2, Ko Willems van 
Dijk1,2,5, Renée de Mutsert3, Johannes W. A. smit6, Hildo J. Lamb4, Ingrid M. Jazet1,2 & 
Patrick C. N. Rensen  1,2
Cholesteryl ester transfer protein (CETP) is mainly expressed by Kupffer cells in the liver. A reduction of 
hepatic triglyceride content (HTGC) by pioglitazone or caloric restriction is accompanied by a decrease 
in circulating CETP. Since GLP-1 analogues also reduce HTGC, we assessed whether liraglutide decreases 
CETP. Furthermore, we investigated the association between HTGC and CETP in a population-based 
cohort. In a placebo-controlled trial, 50 patients with type 2 diabetes were randomly assigned to 
treatment with liraglutide or placebo added to standard care. In this trial and in 1,611 participants of the 
Netherlands Epidemiology of Obesity (NEO) study, we measured HTGC and circulating CETP by proton 
magnetic resonance spectroscopy and ELISA, respectively. The HTGC was decreased in the liraglutide 
group (−6.3%; 95%CI of difference [−9.5, −3.0]) but also in the placebo group (−4.0%; 95%CI[−6.0, 
−2.0]), without between-group differences. CETP was not decreased by liraglutide (−0.05 µg/mL; 
95%CI[−0.13, 0.04]) or placebo (−0.04 µg/mL; 95%CI[−0.12, 0.04]). No association was present 
between HTGC and CETP at baseline (β: 0.002 µg/mL per %TG, 95%CI[−0.005, 0.009]) and between the 
changes after treatment with liraglutide (β: 0.003 µg/mL per %TG, 95%CI[−0.010, 0.017]) or placebo 
(β: 0.006 µg/mL per %TG, 95%CI[−0.012,0.024]). Also, in the cohort n o association between HTGC 
and CETP was present (β: −0.001 µg/mL per SD TG, 95%CI[−0.005, 0.003]). A reduction of HTGC after 
treatment with liraglutide or placebo does not decrease circulating CETP. Also, no association between 
HTGC and CETP was present in a large cohort. These findings indicate that circulating CETP is not 
determined by HTGC.
Clinical Trial Registration: Clinicaltrials.gov (NCT01761318).
Cholesteryl ester transfer protein (CETP) facilitates the transfer of cholesteryl esters from HDL towards 
triglyceride-rich lipoproteins, mainly VLDL, coupled to a net flux of triglycerides from VLDL to HDL1. CETP 
thereby causes a proatherogenic lipoprotein profile, with increased atherogenicity of VLDL particles2. Recently, 
it has been shown that circulating levels of CETP are mainly determined by Kupffer cells, which are the resident 
macrophages of the liver3,4, and that adipose tissue does not relevantly contribute to serum CETP concentration5.
Although Kupffer cells in the liver have been identified as the main source of circulating CETP, the regulation 
of hepatic CETP production is incompletely understood. Previous human studies showed that treatment with 
the peroxisome proliferator-activated receptor (PPAR)-γ agonist pioglitazone6 and prolonged caloric restriction7 
both reduced hepatic triglyceride content, which was accompanied by a decrease in plasma CETP concentration. 
Interestingly, it was recently shown that treatment with liraglutide, a human glucagon-like peptide 1 (GLP-1) ana-
logue, also reduces hepatic steatosis and can even lead to histological resolution of non-alcoholic steatohepatitis 
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(NASH)8. GLP-1 analogues are prescribed to patients with type 2 diabetes to achieve glycemic control, whereby 
they also induce weight loss9,10. However, the exact mechanism of action by which GLP-1 analogues ameliorate 
hepatic steatosis and NASH is still unclear. In rodents, GLP-1 analogues were shown to improve diet-induced 
hepatic steatosis and reduce hepatic macrophage recruitment11,12. Notably, the GLP-1 analogue exendin-4 not 
only decreased hepatic triglycerides but also hepatic CETP gene expression and circulating CETP concentration 
in human CETP expressing transgenic mice12. Since we previously showed that hepatic CETP expression and 
plasma CETP concentration were strongly related with the hepatic Kupffer cell content3, the reduction in CETP 
observed with exendin-4 treatment may be explained by a reduction in Kupffer cells. However, in humans, the 
effects of GLP-1 analogues on CETP production are still unknown.
The aim of the present study was to assess whether a liraglutide-induced reduction in hepatic triglyceride 
content would be accompanied by a reduction in circulating CETP concentration in patients with type 2 diabetes. 
In addition, we also investigated the association between hepatic triglyceride content and circulating CETP con-
centration in a population-based cohort of 1,611 participants.
Materials and Methods
Randomised controlled trial. Study overview and study population. This study used data from the 
MAGNA VICTORIA (MAGNetic resonance Assessment of VICTOza efficacy in the Regression of cardiovas-
cular dysfunction In type 2 diAbetes mellitus) study, a prospective, randomised, double-blind, clinical trial. The 
primary outcome measure of this study was the effect of liraglutide on cardiac function13. In the current manu-
script, we report on secondary and other endpoints. Overweight and obese (BMI ≥ 25 kg/m2) patients with type 
2 diabetes were recruited from November 2013 until March 2016 via advertisements and from the outpatient 
clinics of the Leiden University Medical Center (LUMC, Leiden, the Netherlands), general practitioners, and 
local hospitals. We included patients aged 18–69 years, treated with metformin, and with a glycated haemoglobin 
(HbA1c) ≥ 7.0 and ≤10.0% (53–86 mmol/mol). Concomitant treatment with sulfonylurea derivatives and insulin 
was optional, although the dosage of all glucose-lowering medication needed to be stable for at least 3 months 
prior to participation. Exclusion criteria were use of other glucose-lowering therapy than mentioned above, pres-
ence of renal, hepatic or cardiovascular disease, and contra-indications for magnetic resonance imaging (MRI). 
The trial was approved by the ethics committee of the LUMC and performed in accordance with the principles of 
the revised Declaration of Helsinki. Written informed consent was obtained from all subjects before participation. 
The trial was conducted at the LUMC, and was registered at clinicaltrials.gov (NCT01761318, date of registration 
04/01/2013).
Study design and data collection. At baseline, participants were randomised to receive treatment with liraglu-
tide (Victoza®, Novo Nordisk A/S, Bagsvaerd, Denmark) or placebo by block randomisation with block size of 
4 and stratification 1:1 for sex and insulin use. During the study, all participants, study investigators and out-
come assessors were blinded to treatment allocation. Participants visited the study center at baseline and after 
26 weeks of treatment, after ≥6 h of fasting, for medical history assessment, standard physical examination, col-
lection of venous blood samples and MRI. After 4 and 12 weeks of treatment additional venous blood sam-
ples were collected. The starting dose of the study medication was 0.6 mg per day, which was titrated in two 
weeks to a maximum dose of 1.8 mg per day, if tolerated. In addition to study medication, participants received 
treatment according to current clinical guidelines to achieve optimal glycemic control and regulation of blood 
pressure and cholesterol levels. Body composition was assessed using bioelectrical impedance analysis (BIA; 
Bodystat 1500, Bodystat Ltd., Douglas, UK). All blood samples were centrifuged and stored at −80 °C until 
analysis. Plasma cholesterol and triglyceride concentrations were measured on a Modular P800 analyser (Roche 
Diagnostics, Mannheim, Germany). LDL-cholesterol was calculated according to Friedewald’s formula14. Due 
to changes in laboratory procedures during the study, in a subset of participants HbA1c was assessed with bor-
onate affinity high-performance liquid chromatography (Primus Ultra, Siemens Healthcare Diagnostics, Breda, 
the Netherlands), while in the other patients HbA1c was assessed with ion-exchange high-performance liquid 
chromatography (HPLC) (Tosoh G8, Sysmex Nederland B.V., Etten-Leur, the Netherlands). Plasma CETP con-
centrations were determined by ELISA slightly modified from Niemeijer-Kanters et al.15. In short, plates were 
coated with a combination of monoclonal antibodies TP1 (5 µg/ml) and TP2 (2.5 µg/mL; both from Ottawa 
Heart Institute Research Corporation, Ottawa, Canada) during an overnight incubation at 4 °C. The next day 
plates were blocked with 1% BSA (Sigma Aldrich, Zwijndrecht, the Netherlands) for 2 hours at room temper-
ature. EDTA-plasma samples were 80-fold diluted in Assay buffer containing 1% BSA and 0.1% Triton-X100 
(Biorad, Veenendaal, the Netherlands) and incubated for 2 hours at 37 °C. Autocal (Instruchemie, Delfzijl, the 
Netherlands) was used as a standard. Subsequently, plates were incubated with the secondary antibody TP20 
labeled with digoxigenin (0.33 µg/mL; Ottawa Heart Institute Research Corporation, Ottawa, Canada) for 2 hours 
at 37 °C, followed by 1 hour of incubation with anti-digoxigenin-POD, Fab fragments coupled to peroxidase 
(0.0375 U/mL; Roche Molecular Biochemicals, Mannheim, Germany) at room temperature. Finally, plates were 
incubated with TMB for 15 minutes and, after termination of the reaction with H2O2, absorbance was read at 
450 nm. The interassay variance was <10% and the intraassay variance was <5%.
Proton magnetic resonance spectroscopy. Hepatic triglyceride content was assessed with proton magnetic res-
onance spectroscopy (1H-MRS) on a 3 Tesla Ingenia whole-body MR system (Philips Medical Systems, Best, 
the Netherlands). Subjects were scanned in supine position after at least 6 hours of fasting. The body coil was 
used for transmission and reception was achieved with a 16-element anterior, and a 12-element posterior 
array. The 20 × 20 × 20 mm3 voxel of interest (VOI) was placed in the liver while carefully avoiding contami-
nation of bile ducts and blood vessels. VOI localization was achieved using a PRESS (point resolved spectros-
copy) sequence, with echo time of 35 ms and repetition time of 9 s for the unsuppressed spectra and 3.5 s for 
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the water-suppressed spectra. First order pencil beam B0 shimming, with nine projections, was performed in 
the spectroscopic VOI. Four signal averages (NSA) were acquired without water suppression, and 32 NSA with 
water suppression using the MOIST (Multiply Optimized Insensitive Suppression Train) sequence. Spectra were 
acquired during free-breathing at end-expiration with pencil beam navigator-based respiratory triggering tech-
nique. The navigator voxel was placed at the lung-liver interface. Further movement artefacts were minimalized 
by applying motion tracking that corrected the voxel location according to the navigator position. The excita-
tion bandwidth was 1500 Hz and 1024 samples were acquired resulting in spectral resolution of 1.46 Hz/sample. 
The raw spectral data were processed by an in-house developed program that performed channel weighting, 
phase correction and frequency drift correction. After these steps, signal averages that were >2.5 times the stand-
ard deviation were excluded. Lastly the remaining averages were summed after which the spectra were fitted in 
the time-domain using the Java-based MR User Interface ((jMRUI version 5.0; Katholieke Universiteit Leuven, 
Leuven, Belgium). Before fitting the spectrum residual water signal for the water-suppressed spectra was removed 
using a Hankel-Lanczos singular value decomposition (HLSVD) filter. The advanced method for accurate, robust 
and efficient spectral fitting (AMARES) algorithm was used to fit the resonances to a Gaussian line shape. Hepatic 
triglyceride content was calculated by dividing sum of triglyceride methyl (CH3) and triglyceride methylene 
(CH2) by water + CH3 + CH3 * 100%. All spectra were blinded before analysis.
Statistical analyses. Data are shown as means ± SD, or as median (interquartile range) when not normally 
distributed. Within-group changes were assessed using paired t-tests. We performed an analysis of covariance 
(ANCOVA) to assess between-group differences. Linear regression analyses were performed to determine asso-
ciations between hepatic triglyceride content and plasma CETP concentration, and between the change (Δ) in 
hepatic triglyceride content and the change in plasma CETP level. β and corresponding 95% CI were reported. A 
P-value < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS version 23.0 
for Windows (IBM Corporation, Chicago, IL).
Population-based study. Study overview and study population. The study population was part of the 
Netherlands Epidemiology of Obesity (NEO) study, which is a population-based prospective cohort study of 
6,671 men and women between 45 and 65 years, with an oversampling of persons with a BMI of 27 kg/m2 or 
higher. Participants were recruited from September 2008 until September 2012, and visited the NEO study center 
after an overnight fast of at least 10 h for extensive baseline measurements, including venous blood sampling and 
anthropometry. In a random subgroup of 2,082 participants hepatic triglyceride content was available. The pres-
ent study is a cross-sectional analysis of the baseline measurements of the NEO study. We excluded participants 
with missing data on serum CETP concentration (n = 16), or high alcohol intake according to criteria from the 
World Gastroenterology Organisation16, i.e. >30 g/day for men and >20 g/day for women. Therefore, the present 
study population comprised 1,611 NEO study participants who underwent 1H-MRS of the liver. The NEO study 
was approved by the medical ethics committee of the LUMC and all participants gave written informed consent. 
More detailed information about the study design and data collection has been described previously17.
Data collection. Hepatic triglyceride content was quantified by 1H-MRS on a 1.5 Tesla MR system (Philips 
Medical Systems, Best, the Netherlands). CETP concentrations were measured with ELISA kits according to the 
manufacturer’s instructions (DAIICHI CETP ELISA, Daiichi, Tokyo, Japan), in serum that had undergone one 
previous freeze-thaw cycle. Fasting concentrations of ALT and AST were measured with a Cobas Integra 800 
analyzer (Roche Diagnostics, Mannheim, Germany). More detailed information on covariates can be found in 
the supplementary information.
Statistical analyses. Linear regression analyses were performed to examine the association between hepatic 
triglyceride content and serum CETP concentration. All results from the NEO study were based on anal-
yses weighted towards a reference BMI distribution of the general population, and therefore apply to a 
population-based study without oversampling of individuals with overweight or obesity (see supplementary 
information). As hepatic triglyceride content was not normally distributed, this variable was transformed to the 
natural logarithm. For the purpose of interpretation, beta coefficients from linear regression analyses were mul-
tiplied by ln(1.1), and the difference in serum CETP concentration with corresponding 95%CI was expressed 
per 10% relative increase in hepatic triglyceride content. The crude model (Model 1) was adjusted for age and 
sex (Model 2), and subsequently ethnicity, smoking status, alcohol intake and physical activity were added as 
confounding variables (Model 3). Analyses were performed using STATA Statistical Software (Statacorp, College 
Station, Texas, USA), version 12.0.
Results
Randomised controlled trial. Population characteristics. Participants were included between December 
2013 and September 2015 with the last participant visiting in March 2016. Fifty participants were included, of 
whom 24 were randomised to receive liraglutide and 26 to receive placebo. One participant of the liraglutide 
group was withdrawn from the study before starting treatment due to claustrophobia and was not included in 
the analyses. Another participant of the liraglutide group did not finish the study due to misdiagnosis of type 2 
diabetes and one patient of the placebo group was lost to follow-up due to imprisonment, but the baseline meas-
urements of both participants were used for analyses. Three serious adverse events occurred that were not related 
to study drug use. As shown in Table 1, baseline characteristics of the participants in both treatment groups were 
comparable. Individuals were 59.9 ± 6.2 years old in the liraglutide group, vs 59.2 ± 6.8 years in the placebo group, 
with a body weight of 98.4 ± 13.8 vs 94.5 ± 13.1 kg and BMI of 32.6 ± 4.4 vs 31.6 ± 3.4 kg/m2, respectively. Of all 49 
participants included in the study, 40 participants used lipid lowering drugs at the start of the study.
4Scientific RepoRts |          (2019) 9:9996  | https://doi.org/10.1038/s41598-019-45593-2
www.nature.com/scientificreportswww.nature.com/scientificreports/
A decrease in hepatic triglyceride content was not accompanied by a change in circulating CETP. Treatment with 
liraglutide for 26 weeks decreased body weight in contrast to treatment with placebo (−4.3 ± 3.8 kg vs 0.1 ± 2.5 kg; 
mean change from baseline (liraglutide vs placebo): −4.5 kg; 95%CI [−6.4, −2.6]), as shown in Table 2. 
Furthermore, treatment with liraglutide decreased hepatic triglyceride content (−6.3%; 95%CI of difference 
[−9.5, −3.0]), but hepatic triglyceride content was also decreased in the placebo group (−4.0%; 95%CI [−6.0, 
−2.0]), without between-group differences (mean change from baseline (liraglutide vs placebo): −2.1%; 95%CI 
[−5.3, 1.0]). Interestingly, this decrease in hepatic triglycerides in both treatment groups was not accompanied 
by a decrease in circulating CETP after 26 weeks of intervention. Also, after 4 and 12 weeks of intervention, CETP 
was not affected in both the liraglutide group and the placebo group (not shown). Figure 1 shows that hepatic 
triglyceride content was not associated with CETP at baseline (β: 0.002 µg/mL per 1% increase in hepatic triglyc-
eride content; 95%CI [−0.005, 0.009]). Furthermore, there was no association between the changes of both vari-
ables after treatment with liraglutide (β: 0.003 µg/mL; 95%CI [−0.010, 0.017]) or placebo (β: 0.006 µg/mL; 95%CI 
[−0.012, 0.024]). At baseline, circulating CETP concentration was lower in participants using lipid lowering drugs 
(0.80 ± 0.23 µg/mL; 82% of participants) than in participants not using lipid lowering drugs (0.93 ± 0.27 µg/mL; 
18% of participants), mean difference 0.14 µg/mL; 95%CI of difference [−0.08, 0.35]). Furthermore, while 
HDL-cholesterol was not affected, total cholesterol, LDL-cholesterol and triglycerides were decreased in both 
groups. Finally, HbA1c was improved after treatment with liraglutide (−1.1%; 95%CI of difference [−1.5, −0.6]), 
but also after treatment with placebo (−0.7% 95%CI of difference [−1.1, −0.3]); without between-group differ-
ences (mean change from baseline (liraglutide vs placebo): -0.3%; 95%CI [−0.8, 0.2]).
Population-based study. Population characteristics. Demographic and clinical characteristics of the NEO 
study population are presented in Table 3. While mean BMI was lower in women than in men, mean total body fat 
was higher in women. Hepatic triglyceride content ranged from 0.2% to 62.9% and was lower in women than in 
men. Serum CETP ranged from 0.88 to 5.02 µg/mL. Men had a lower serum CETP concentration (2.38 ± 0.62 µg/







Age (years) 59.9 ± 6.2 59.2 ± 6.8
Sex (n (%))
Men 14 (61%) 15 (58%)
Women 9 (39%) 11 (42%)
Diabetes duration (years) 11.3 ± 6.4 10.9 ± 7.1
Alcohol use (no. (%)) 9 (39%) 10 (39%)
Clinical parameters
Body weight (kg) 98.4 ± 13.8 94.5 ± 13.1
BMI (kg/m2) 32.6 ± 4.4 31.6 ± 3.4
Total fat mass (%) 36.1 ± 10.3 36.6 ± 8.8
Hepatic triglyceride content (%) 18.1 ± 11.2 18.4 ± 9.4
Fasting concentrations
CETP (µg/mL) 0.84 ± 0.22 0.81 ± 0.26
Total cholesterol (mmol/L) 4.82 ± 1.02 4.80 ± 1.02
HDL-cholesterol (mmol/L) 1.22 ± 0.25 1.30 ± 0.39
LDL-cholesterol (mmol/L) 2.60 ± 0.86 2.55 ± 0.91
Triglycerides (mmol/L) 2.19 ± 1.51 2.10 ± 1.09
Glucose (mmol/L) 8.7 ± 2.7 7.3 ± 1.7
HbA1c (%) 8.3 ± 1.1 8.1 ± 0.9
HbA1c (mmol/mol) 66.7 ± 11.5 64.7 ± 10.2
AST (IU/L) 31 ± 11 35 ± 21
ALT (IU/L) 15 ± 7 13 ± 5
Concomitant drug use
Lipid lowering drugs (no. (%)) 21 (91%) 19 (73%)
Metformin (g/day) 2.1 ± 0.7 2.0 ± 0.5
Sulfonylureas (no. (%)) 6 (26%) 8 (31%)
Insulin (no. (%)) 15 (65%) 17 (65%)
Insulin (units) 70 ± 46 69 ± 58
Table 1. Baseline characteristics of participants from the MAGNA VICTORIA study. Results are presented 
as n (%) or mean ± SD. n = 49. Missing data: n = 2 for alcohol use and n = 2 for hepatic triglyceride content 
in placebo-group. ALT: alanine transaminase, AST: aspartate transaminase, CETP: cholesteryl ester transfer 
protein, HbA1c: glycated haemoglobin.
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lower in participants using lipid lowering drugs (2.13 ± 0.72 µg/mL) compared with participants not using lipid 
lowering drugs (2.56 ± 0.62 µg/mL) (difference −0.43; 95%CI [−0.54, −0.32]).
Hepatic triglyceride content was not associated with circulating CETP in the general population. As shown in 
Fig. 2, hepatic triglyceride content was not associated with serum CETP concentration in the NEO study, neither 
in men, women, lipid lowering drug users or non-users of lipid lowering drugs. As can be appreciated from Suppl. 
Table 1, a 10% increase in hepatic triglyceride content was associated with a −0.001 µg/mL (95%CI [−0.005, 
0.003]) difference in serum CETP. Similar associations around the null were observed after adjustment for con-
founding variables.
Discussion
In this double-blind, randomised placebo-controlled trial, we observed that a reduction in hepatic triglyceride 
content after treatment with liraglutide, but also with placebo, was not accompanied by a reduction in circulating 
CETP concentration. In line, we found no evidence for an association between hepatic triglyceride content and 
circulating CETP concentration in a large population-based cohort study (n = 1,611). Our findings imply that 
plasma CETP concentration is not determined by hepatic triglyceride content.
Our observation that the hepatic triglyceride content decreased after liraglutide treatment is in accordance 
with results from previous studies in humans and rodents8,11. However, this decrease was also observed in the 
placebo group. Furthermore, although the GLP-1 analogue exendin-4 decreased hepatic CETP gene expres-
sion and CETP concentration in rodents12, we found no effect of liraglutide treatment on the circulating CETP 
Characteristic
Mean ± SD change from baseline 
to 26 weeks Mean [95%CI] 
changes from baseline 
(liraglutide vs placebo) P value
Liraglutide 
(n = 22) Placebo (n = 25)
Clinical parameters
Body weight (kg) −4.3 ± 3.8 0.1 ± 2.5 −4.5 [−6.4, −2.6] <0.001
BMI (kg/m2) −1.5 ± 1.3 0.1 ± 0.8 −1.5 [−2.2, −0.9] <0.001
Hepatic triglyceride content (%) −6.3 ± 7.1 −4.0 ± 4.6 −2.1 (−5.3, 1.0) 0.174
Metabolic factors
CETP (µg/mL) −0.05 ± 0.20 −0.04 ± 0.18 0.00 [−0.10, 0.11] 0.977
Total cholesterol (mmol/L) −0.72 ± 0.89 −0.46 ± 0.56 −0.22 [−0.59, 0.15] 0.231
HDL-cholesterol (mmol/L) −0.02 ± 0.14 0.05 ± 0.25 −0.08 [−0.20, 0.05] 0.222
LDL-cholesterol (mmol/L) −0.44 ± 0.51 −0.24 ± 0.52 −0.17 [−0.44, 0.10] 0.218
Triglycerides (mmol/L) −0.50 ± 1.12 −0.60 ± 0.98 0.23 [−0.11, 0.56] 0.177
Glucose (mmol/L) −1.7 ± 2.2 −0.6 ± 2.2 −0.5 [−1.7, 0.7] 0.434
HbA1c (%) −1.1 ± 1.0 −0.7 ± 0.9 −0.3 [−0.8, 0.2] 0.265
HbA1c (mmol/mol) −11.6 ± 11.1 −7.7 ± 9.4 −2.9 [−8.1, 2.3] 0.265
AST (IU/L) −6 ± 11 −12 ± 22 2 [−3, 6] 0.459
ALT (IU/L) 16 ± 12 14 ± 10 1 [−5, 7] 0.778
Table 2. Body weight, hepatic triglyceride content and metabolic factors change from baseline to after 26 
weeks of treatment in the MAGNA VICTORIA study. Results are presented as mean ± SD. n = 47. Missing 
data: n = 2 for hepatic triglyceride content in the placebo group, n = 1 for hepatic triglyceride content, n = 1 
for LDL-cholesterol and n = 1 for glucose in the liraglutide group. ALT: alanine transaminase, AST: aspartate 
transaminase, CETP: cholesteryl ester transfer protein, HbA1c: glycated haemoglobin.
Figure 1. Associations between hepatic triglyceride content and plasma CETP levels in the MAGNA 
VICTORIA study. Hepatic triglyceride content in relation to plasma CETP level, n = 47 (A), and change of 
hepatic triglyceride content in relation to change in plasma CETP level, liraglutide n = 21, placebo n = 23 (B). 
CETP: cholesteryl ester transfer protein.
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concentration. These data are corroborated by our finding that hepatic triglyceride content was not associated 
with circulating CETP concentration in the large population-based NEO cohort. There was also no association 
present after stratification by lipid lowering drug use, which implies that lipid lowering drugs do not mediate or 
influence the effects of hepatic triglyceride content on CETP concentration. Nevertheless, our data seem counter-
intuitive, as previous studies did report a decrease in CETP upon other interventions that reduce hepatic steatosis. 
For example, Jonker et al.18 showed that the PPARγ agonist pioglitazone decreased hepatic triglyceride content 
(from 6 to 4%) as well as CETP concentration (-12%), while the decrease of circulating CETP correlated with 
the decrease in hepatic triglyceride content. Notably, in their study both the hepatic triglyceride and circulating 
CETP concentration at baseline were lower compared to our study and the reduction of hepatic triglyceride 
content induced by pioglitazone was smaller than the decrease in the liraglutide group in the present study. In 
another study, patients with type 2 diabetes received a 16-week very low calorie diet, which resulted in dramatic 
weight loss and a large reduction in hepatic triglyceride content (from 21 to 3%) as well as CETP concentration 
(−18%)7. After gastric banding surgery, with associated substantial weight loss, similar large reductions in CETP 
concentration have been described3,19.
Interestingly, hepatic triglyceride content was not only decreased in the liraglutide-treated group, but also 
in the placebo group. This is probably due to treatment of participants in both groups according to current clin-
ical guidelines, which resulted in an intensified treatment with glucose-lowering drugs in the placebo-group, 
while in the liraglutide-group such treatment could be decreased. Both groups showed improved glucoregulation, 
evidenced by decreased HbA1c after treatment. It is thus likely that intensified treatment of the placebo group 
decreased the rate of hepatic lipogenesis and consequently lowered intrahepatic triglyceride storage, resulting in 
increased hepatic insulin sensitivity that lowers glucose production20,21. Notably, similar to treatment with lira-
glutide, the reduction in hepatic triglycerides caused by placebo treatment was not accompanied by a reduction 
in circulating CETP.
Characteristic Men Women
Proportion of participants (%) 45 55
Ethnicity (% whites) 95 95
Age (year) 55.8 ± 6.5 55.1 ± 5.5
Alcohol use (% users) 89 82
Alcohol intake (g/day) 12.1 ± 9.5 5.6 ± 5.0
BMI (kg/m2) 26.4 ± 3.5 25.4 ± 4.2
Total body fat (%) 24.2 ± 5.7 36.3 ± 6.1
Fasting concentrations
CETP (µg/mL) 2.38 ± 0.62 2.64 ± 0.64
Total cholesterol (mmol/L) 5.56 ± 1.00 5.81 ± 1.03
HDL-cholesterol (mmol/L) 1.31 ± 0.36 1.72 ± 0.43
LDL-cholesterol (mmol/L) 3.62 ± 0.93 3.59 ± 0.95
Triglycerides (mmol/L) 1.38 ± 0.89 1.09 ± 0.68
ALT (IU/L) 28.4 ± 13.0 21.3 ± 7.7
AST (IU/L) 25.8 ± 7.3 22.9 ± 6.2
HbA1c (%) 5.4 ± 0.6 5.3 ± 0.3
HbA1c (mmol/mol) 35.5 ± 6.7 34.7 ± 3.6
Comorbidity and medication
Hepatic triglyceride content (%) 3.4 (1.9, 7.7) 1.7 (1.1, 4.5)
Diabetes (% yes) 6 4
Impaired fasting glucose (% yes) 10 5
Oral glucose lowering drugs (% users) 3 1
Insulin (% users) 0.04 0.5
Oral glucose lowering drugs and insulin (% users) 0.8 0.1
Cardiovascular disease (% yes) 5 4
Lipid lowering drugs (% users) 12 5
Table 3. Characteristics of participants from the NEO study population who underwent proton magnetic 
resonance spectroscopy of the liver to assess hepatic triglyceride content, stratified by sex. Results were based 
on analyses weighted towards the BMI distribution of the general population (n = 1,611) and presented 
as mean ± SD, median (interquartile range) or percentage. Missing data: n = 2 for ethnicity, n = 1 for total 
body fat, n = 5 for plasma total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, ALT and 
AST concentrations, n = 15 for HbA1c concentration, n = 6 for presence of diabetes, n = 5 for presence of 
cardiovascular disease. ALT: alanine transaminase, AST: aspartate transaminase, BMI: body mass index, 
CETP: cholesteryl ester transfer protein, HbA1c: glycated haemoglobin, HDL: high-density lipoprotein, IU: 
international unit, LDL: low-density lipoprotein, NEO: Netherlands Epidemiology of Obesity.
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It is interesting to speculate on the mechanism by which GLP-1 analogues may influence plasma CETP 
concentration in humans. Notably, in contrast to previous studies7,18, our findings show that liraglutide and 
placebo-induced lowering of hepatic triglycerides is not accompanied by decreases in plasma CETP concen-
tration. We have previously shown that the GLP-1 analogue exendin-4 decreased plasma CETP concentration, 
which was accompanied by a reduction in the number of hepatic macrophages12, the main source of CETP pro-
duction. The reduction in hepatic macrophage content by exendin-4 attributes to reduced macrophage recruit-
ment from the circulation and/or enhanced macrophage elimination from the liver. Indeed, in rodents, exendin-4 
decreased the hepatic gene expression of monocyte chemotactic protein-111,12, which mediates monocyte/mac-
rophage recruitment from the circulation to tissue. Since Panjwani et al.22 reported that the GLP-1 receptor is 
undetectable in isolated macrophages and hepatocytes, the effect of exendin-4 on hepatic macrophage content is 
unlikely mediated via the GLP-1 receptor. However, the exact action of exendin-4 on macrophage recruitment 
and elimination is unclear, and whether other GLP-1 analogues exert the same beneficial effects on hepatic mac-
rophage content needs to be further investigated. It is possible that this is an effect specific for exendin-4 not 
shared by liraglutide. Furthermore, it is possible that, in contrast to in rodents, GLP-1 receptor agonists in general, 
or the applied dose of liraglutide specifically, fail to reduce the hepatic macrophage content in humans. Indeed, in 
the LEAN-trial, in which patients with NASH were treated with liraglutide, no effects were observed on lobular 
inflammation and overall non-alcoholic fatty liver disease (NAFLD) activity score8. Collectively, it is likely that 
liraglutide fails to affect hepatic macrophages to an extent that is sufficient to decrease CETP concentration.
In this light, it is interesting to note that we previously studied the association of metabolic liver inflammation 
with hepatic and circulating CETP23. We showed that metabolic liver inflammation, as a histologically determined 
component of NAFLD in obese individuals, did not associate with CETP measures (i.e. liver CETP, liver CETP 
positive cells and circulating CETP concentrations). These data are in line with the findings of the current study, as 
apparently, metabolic triggers of liver damage do not decrease CETP production. Interestingly, infection-related 
liver inflammation, as induced by Gram-negative bacteria, strongly decreases CETP production by the liver24. 
As both metabolic induced liver steatosis and inflammation23 do not affect CETP production by Kupffer cells, it 
seems that NAFLD does not mimic the strong effects of Gram-negative bacterial infections on the hepatic expres-
sion and production of CETP by Kupffer cells. This suggests that metabolically-induced and infection-related 
inflammation may have different effects on the expression and production of CETP by Kupffer cells.
Preclinical studies using mice and cultured cells have shown that the Liver X Receptor α (LXRα) plays a cru-
cial role in regulation CETP expression. The natural ligands of LXRα are oxysterols25,26. In line, it has been shown 
Figure 2. Associations between hepatic triglyceride content and serum CETP concentrations in the NEO 
study population. Crude associations between hepatic triglyceride content and serum CETP concentration, 
stratified by sex (A) and lipid lowering drug use (B). Results were based on analyses weighted towards the BMI 
distribution of the general population (n = 1,611). CETP: cholesteryl ester transfer protein; NEO: Netherlands 
Epidemiology of Obesity.
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that lipid lowering drugs decrease total hepatic cholesterol content and levels of oxysterols, thereby diminish-
ing LXRα activation and CETP expression in CETP-transgenic mice27. Therefore, the lower levels of circulating 
CETP in participants using lipid lowering drugs in our intervention trial as well as in our cohort study are likely 
explained by attenuated CETP expression by reduced oxysterol-mediated LXRα signalling. It has previously been 
proposed that a decreased hepatic triglyceride content upon an intervention with caloric restriction or piogli-
tazone may reduce CETP concentration via this LXRα-dependent mechanism, as a reduction in triglycerides 
would be accompanied by a reduction in the natural LXRα agonists7,18. However, since in our trial a reduction of 
hepatic triglyceride content was not accompanied by a reduction of CETP concentration, our results imply that 
interventions on hepatic triglyceride content per se do not affect hepatic oxysterols and thereby LXRα-mediated 
CETP production. With these new insights, we speculate that decreased CETP concentration previously found 
after interventions with pioglitazone and caloric restriction might be better explained by a reduction of the num-
ber of Kupffer cells than by a decreased hepatic oxysterol content.
The strengths of this study are the randomised placebo-controlled trial design, and the availability of data on 
hepatic triglyceride content and CETP concentration from a large population-based cohort. A limitation is that 
the study population of the NEO study was predominantly white and results may therefore not apply to other 
ethnical groups. Furthermore, the study design of the trial, in which in addition to study medication patients 
received treatment according to current clinical guidelines, is another possible limitation, since we were not able 
to investigate the effects of liraglutide only. Also, use of co-medication could interfere with the effects of liraglu-
tide on CETP. Nevertheless, this study design increases the generalizability of our findings.
In summary, in a randomised placebo-controlled trial, we showed that liraglutide treatment and placebo 
intervention on top of standard treatment with glucose lowering drugs decrease hepatic triglyceride content 
without decreasing plasma CETP concentration. We confirmed the absence of an association between hepatic 
triglyceride content and CETP in a large population-based cohort study. This implies that circulating CETP con-
centration is not determined by hepatic triglyceride content.
Data Availability
The datasets generated and/or analysed during the current study are not publicly available but are available from 
the corresponding author on reasonable request.
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